ABIONYX Pharma SA (ABNX) AI Stock Analysis

• Market Cap: €145.17M
• Dividend Yield: N/A
• Average Volume (3M): 284.77K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.74
• Revenue Growth: -10.91%
• EPS Growth: -25.57%
• Country: FR
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 34,931,010
• 10 Day Avg. Volume: 172,880
• 30 Day Avg. Volume: 284,772
• PEG Ratio: -1.09
• Price to Book (P/B): 5.40
• Price to Sales (P/S): 8.72
• P/FCF Ratio: -11.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: €4.50 ▲(16.28% Upside)

The overall stock score of 50 reflects significant financial challenges faced by ABIONYX Pharma SA, with persistent losses and liquidity concerns being the most impactful factors. While technical analysis shows positive momentum, the poor valuation due to negative earnings and lack of dividends further weighs down the score.

ABIONYX Pharma SA Business Overview & Revenue Model

Company Description

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.

How the Company Makes Money

ABIONYX Pharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company makes money by advancing its product candidates through various stages of clinical trials and subsequently licensing or partnering with larger pharmaceutical companies for further development and market access. Key revenue streams include milestone payments from partnerships, royalties on product sales once commercialized, and potential upfront payments from licensing agreements. Additionally, the company may benefit from government grants and funding aimed at supporting innovative biopharmaceutical research.

ABIONYX Pharma SA Financial Statement Overview

Summary

ABIONYX Pharma SA's financial performance is concerning, with declining revenues, persistent losses, and liquidity issues. The income statement shows a negative EBIT margin of -97.83% and net profit margin of -95.65%. The balance sheet indicates moderate leverage but poor profitability with a negative return on equity of -59.28%. Cash flow analysis reveals negative free cash flow, underscoring liquidity challenges.

Income Statement

ABIONYX Pharma SA's income statement indicates significant challenges. The company experienced a decline in revenue by 0.86% from 2023 to 2024, and gross profit margin stands at a low 19.57% for 2024, reflecting high cost relative to revenue. The company also reported a negative EBIT margin of -97.83% and a net profit margin of -95.65%, highlighting ongoing operational inefficiencies and substantial losses.

Balance Sheet

The balance sheet shows moderate financial health, with a debt-to-equity ratio of 0.37, suggesting manageable leverage. However, the equity ratio is 55.20%, indicating a fair level of reliance on equity financing. Return on equity is negative at -59.28%, reflecting the company's unprofitable operations.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow, indicating potential liquidity issues. The free cash flow to net income ratio is 0.82, suggesting cash flow challenges relative to net losses. Additionally, there is a slight improvement in operating cash flow to net income ratio from -1.05 in 2023 to -0.82 in 2024, yet it remains negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.38M	4.60M	4.64M	5.25M	675.00K	0.00
Gross Profit	827.00K	844.00K	618.00K	636.00K	259.00K	-80.00K
EBITDA	-226.50K	-4.93M	-4.84M	-4.01M	-7.42M	-2.33M
Net Income	-4.59M	-4.40M	-3.52M	-4.21M	-5.82M	-1.89M
Balance Sheet
Total Assets	12.98M	13.45M	14.83M	15.82M	21.83M	10.29M
Cash, Cash Equivalents and Short-Term Investments	3.38M	3.23M	4.10M	4.05M	7.93M	9.15M
Total Debt	4.12M	2.76M	3.39M	4.01M	4.96M	24.00K
Total Liabilities	7.56M	6.03M	6.91M	8.65M	11.15M	3.66M
Stockholders Equity	5.41M	7.42M	7.92M	7.17M	10.68M	6.63M
Cash Flow
Free Cash Flow	-3.40M	-3.60M	-3.83M	-3.53M	-6.86M	-747.00K
Operating Cash Flow	-3.43M	-3.60M	-3.70M	-3.36M	-6.69M	-599.00K
Investing Cash Flow	-209.00K	-100.00K	-130.00K	-175.00K	1.34M	-125.00K
Financing Cash Flow	1.74M	2.80M	3.89M	-194.00K	3.97M	1.55M

ABIONYX Pharma SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.87
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABNX, the sentiment is Positive. The current price of 3.87 is above the 20-day moving average (MA) of 3.84, above the 50-day MA of 3.73, and above the 200-day MA of 1.93, indicating a bullish trend. The MACD of 0.20 indicates Positive momentum. The RSI at 50.45 is Neutral, neither overbought nor oversold. The STOCH value of 26.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ABNX.

ABIONYX Pharma SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABNX	50 Neutral	€145.17M	-31.60	-62.40%	―	-10.91%	-25.57%
ALDVI	49 Neutral	€24.45M	―	―	―	101.95%	35.55%
ALGAE	49 Neutral	€43.67M	-4.07	-33.26%	―	59.05%	57.39%
SIGHT	41 Neutral	€23.03M	-1.02	―	―	-92.35%	63.25%
ALVAL	41 Neutral	€14.45M	-1.01	―	―	―	―